17 research outputs found
Colossal dielectric constants in transition-metal oxides
Many transition-metal oxides show very large ("colossal") magnitudes of the
dielectric constant and thus have immense potential for applications in modern
microelectronics and for the development of new capacitance-based
energy-storage devices. In the present work, we thoroughly discuss the
mechanisms that can lead to colossal values of the dielectric constant,
especially emphasising effects generated by external and internal interfaces,
including electronic phase separation. In addition, we provide a detailed
overview and discussion of the dielectric properties of CaCu3Ti4O12 and related
systems, which is today's most investigated material with colossal dielectric
constant. Also a variety of further transition-metal oxides with large
dielectric constants are treated in detail, among them the system La2-xSrxNiO4
where electronic phase separation may play a role in the generation of a
colossal dielectric constant.Comment: 31 pages, 18 figures, submitted to Eur. Phys. J. for publication in
the Special Topics volume "Cooperative Phenomena in Solids: Metal-Insulator
Transitions and Ordering of Microscopic Degrees of Freedom
Mutagenic activity in somatic and germ cells following chronic inhalation of sulfur mustard
A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia
The optimal dose of cytarabine for induction chemotherapy is unknown. Most studies have utilized doses of 100â200 mg/m2/d, although higher doses have been proposed to increase the concentration of the active metabolite araâCTP within leukaemia cells. To address this question 101 adults with newly diagnosed acute myeloid leukaemia were randomized to receive treatment with daunorubicin and either conventionalâdose cytarabine (200 mg/m2/d by continuous infusion) or an intermediateâdose of cytarabine (500 mg/m2 every 12 h). 36/51 (71%) patients assigned to conventionalâdose cytarabine achieved complete remission compared to 37/50 (74%) who achieved remission with intermediateâdose cytarabine (P = 0.9). Patient age significantly affected remission rate. 8/17 patients age >60 assigned to conventionalâdose cytarabine and 10/17 assigned to intermediateâdose cytarabine achieved complete remission compared to 27/33 patients under age 60 assigned to the conventional dose and 28/34 patients assigned to the intermediate dose arm (P=0.004). Actuarial 4âyear diseaseâfree survival for patients assigned to conventionalâdose cytarabine was 20.16% versus 28.17% for patients assigned to intermediateâdose cytarabine (P=0â9). We conclude that intermediate dose cytarabine did not substantially improve results of induction chemotherapy for acute myeloid leukaemia